Discontinuation of empirical antibiotic therapy in neutropenic leukaemia patients with fever of unknown origin is ethical

Clinical Microbiology and Infection

Volumn 21, Issue 3, 2015, Pages e25-e27

  Orasch, C ^a   Averbuch, D ^b   Mikulska, M ^c   Cordonnier, C ^d   Livermore, D M ^e   Gyssens, I C ^f,g,h   Klyasova, G ⁱ   Engelhard, D ^b   Kern, W ^j   Viscoli, C ^c   Akova, M ^k   Marchetti, O ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c UNIVERSITY OF GENOA   (Italy)

^d HENRI MONDOR HOSPITAL   (France)

^e UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^g CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^h HASSELT UNIVERSITY   (Belgium)

ⁱ NATIONAL RESEARCH CENTER FOR HEMATOLOGY   (Russian Federation)

^j UNIVERSITY OF FREIBURG   (Germany)

^k HACETTEPE UNIVERSITY   (Turkey)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ACUTE MYELOBLASTIC LEUKEMIA; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; BACTERIAL TRANSLOCATION; DISEASE COURSE; DRUG WITHDRAWAL; HEMODYNAMICS; HIGH RISK PATIENT; HUMAN; LETTER; MEDICAL ETHICS; MUCOSA INFLAMMATION; NEUTROPENIA; NEUTROPHIL COUNT; PRIORITY JOURNAL; PROPHYLAXIS; PYREXIA IDIOPATHICA; SEPTIC SHOCK; TREATMENT WITHDRAWAL; COMPLICATION; ETHICS; FEMALE; FEVER OF UNKNOWN ORIGIN; MALE;

ANTI-BACTERIAL AGENTS; FEMALE; FEVER OF UNKNOWN ORIGIN; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; NEUTROPENIA; WITHHOLDING TREATMENT;

EID: 84929940667     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2014.10.014     Document Type: Letter

References (5)

1. Micol J., Chahine C., Woerther P., Ghez D., Netzer F., Dufour C., et al. Discontinuation of empirical antibiotic therapy in neutropenic acute myeloid leukaemia patients with fever of unknown origin: is it ethical?. Clin Microbiol Infect 2014, 20:453-455.
2. Viscoli C., Cometta A., Kern W., Bock R., Paesmans M., Crokaert F., et al. Piperacillin-tazobactam monotherapy in high-risk febrile and neutropenic cancer patients. Clin Microbiol Infect 2006, 12:212-216.
3. Akova M., Paesmans M., Calandra T., Viscoli C. A European Organization for Research and Treatment of Cancer-International Antimicrobial Therapy Group Study of secondary infections in febrile, neutropenic patients with cancer. Clin Infect Dis 2005, 40:239-245. International Antimicrobial Therapy Group of the European Organization for Research and Treatment of Cancer.
4. Bucaneve G., Castagnola E., Viscoli C., Leibovici L., Menichetti F. Quinolone prophylaxis for bacterial infections in afebrile high risk neutropenic patients. EJC Suppl 2007, 5:5-12.
5. Leibovici L., Paul M., Cullen M., Bucaneve G., Gafter-Gvili A., Fraser A., et al. Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. Cancer 2006, 107:1743-1751.